CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Ultima Genomics›
Products & Services›
UG200 Series›
Analysis
UG200 Series logo

Ultima Genomics› offers UG200 Series

ProductOperating Status: Currently Offered

UG200 Series sequencers provide high-throughput genomic sequencing with single- and dual-wafer configurations.

Loading
Overview
Analysis

UG200 Series - Research Notes

  • Ultima states that the UG200 Series can run continuously with automated wafer handling and hot-swappable reagent drawers. Its product specifications distinguish the single-wafer and dual-wafer systems by output and describe an in-field upgrade from UG200 to Ultra.

    The company also describes a smaller footprint and weight than its preceding platform, which may ease deployment in laboratories. These are the manufacturer’s stated capabilities; the product page does not provide an independent comparison with every competing sequencer.

  • Ultima Genomics announced the UG200 Series on February 23, 2026, ahead of the Advances in Genome Biology and Technology conference. The announcement introduced a single-wafer UG200 and a dual-wafer UG200 Ultra.

    The launch release said the systems were available for purchase, with shipments expected to begin in the second quarter of 2026. The current product page presents both configurations as members of one instrument series.

  • The UG200 architecture uses a 200-millimeter open wafer, rotational imaging, and reagent delivery rather than a conventional flow cell. The manufacturer says pooled samples can be loaded for continuous operation with limited manual intervention.

    The official specifications separate run output by read length and by single-wafer versus dual-wafer configuration. Buyers therefore need to compare the required read length, library type, and annual sample volume before treating the two configurations as interchangeable.

  • The UG200 Series is Ultima Genomics’ sequencing instrument family with a single-wafer UG200 and a dual-wafer UG200 Ultra. Both configurations use the same open-wafer architecture and target high-throughput genomic projects.

    The product page states that the UG200 can be upgraded in the field to the Ultra configuration. It describes whole-genome, single-cell, and proteomic applications and gives separate output specifications for the two systems.